GREEN VISION BIOTECHNOLOGY CORP.: 10-K filed 2017-05-01
What GREEN VISION BIOTECHNOLOGY CORP. reported in its annual report filed 2017-05-01 (fiscal FY 2017): 9 published measures, 18 facts as tagged in accession 0001640334-17-000808.
This filing
- Form
- 10-K (annual report)
- Filed
- 2017-05-01
- Fiscal period
- fiscal FY 2017
- Accession
- 0001640334-17-000808 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GREEN VISION BIOTECHNOLOGY CORP. filings.
Reported measures
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-31 | 106,648 | USD | |
| At 2016-01-31 | 37,035 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-31 | -106,648 | USD | |
| At 2016-01-31 | -37,035 | USD | |
| At 2015-01-31 | -16,823 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-01-31 | 175 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-02-01 to 2017-01-31 | -69,613 | USD | 366 |
| 2015-02-01 to 2016-01-31 | -37,560 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-31 | -150,576 | USD | |
| At 2016-01-31 | -80,963 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-31 | 106,648 | USD | |
| At 2016-01-31 | 37,035 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-02-01 to 2017-01-31 | 69,613 | USD | 366 |
| 2015-02-01 to 2016-01-31 | 37,560 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-01-31 | 60,790,000 | shares | |
| At 2016-01-31 | 60,790,000 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-02-01 to 2017-01-31 | 69,613 | USD | 366 |
| 2015-02-01 to 2016-01-31 | 37,560 | USD | 365 |
Inspect the source
- Entity
- GREEN VISION BIOTECHNOLOGY CORP. / CIK 0001571804
- Captured
- SEC response SHA-256
f900c79f6de11454e9e92e93c55c93d276ffa598a95106526ff88cb826780ecf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001571804.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))